• Study Resource
  • Explore Categories
    • Arts & Humanities
    • Business
    • Engineering & Technology
    • Foreign Language
    • History
    • Math
    • Science
    • Social Science

    Top subcategories

    • Advanced Math
    • Algebra
    • Basic Math
    • Calculus
    • Geometry
    • Linear Algebra
    • Pre-Algebra
    • Pre-Calculus
    • Statistics And Probability
    • Trigonometry
    • other →

    Top subcategories

    • Astronomy
    • Astrophysics
    • Biology
    • Chemistry
    • Earth Science
    • Environmental Science
    • Health Science
    • Physics
    • other →

    Top subcategories

    • Anthropology
    • Law
    • Political Science
    • Psychology
    • Sociology
    • other →

    Top subcategories

    • Accounting
    • Economics
    • Finance
    • Management
    • other →

    Top subcategories

    • Aerospace Engineering
    • Bioengineering
    • Chemical Engineering
    • Civil Engineering
    • Computer Science
    • Electrical Engineering
    • Industrial Engineering
    • Mechanical Engineering
    • Web Design
    • other →

    Top subcategories

    • Architecture
    • Communications
    • English
    • Gender Studies
    • Music
    • Performing Arts
    • Philosophy
    • Religious Studies
    • Writing
    • other →

    Top subcategories

    • Ancient History
    • European History
    • US History
    • World History
    • other →

    Top subcategories

    • Croatian
    • Czech
    • Finnish
    • Greek
    • Hindi
    • Japanese
    • Korean
    • Persian
    • Swedish
    • Turkish
    • other →
 
Profile Documents Logout
Upload
POPON-S
POPON-S

... place protected from direct sunlight and at low humidity (If a top of the bottle is poorly closed, the product may be transformed due to humidity and others. Close the top of bottle tightly after every use). (2) Keep this product out of the reach of children. (3) Do not transfer the product into ano ...
Unsafe Drugs: Congressional Silence is Deadly
Unsafe Drugs: Congressional Silence is Deadly

... marketing begins, user-fee revenues may not be used to assess them. The safety of drugs already on the market is hardly thus ensured by this legislation. ...
OTC Meds MATA 2016
OTC Meds MATA 2016

... A division of the Department of Health and Human Services (Which also administers medicare/medicaid) 800 approved ingredients that are combined to create over 100000 OTC drugs ...
investigational drug services in the hospital
investigational drug services in the hospital

... Objectives of clinical trial should be explained, including risks and benefits, and any alternative therapies available. Outlines the responsibility of the investigator to keep the subject informed about additional information that becomes available as the study progresses ...
I. Introduction
I. Introduction

... Introduction Pharmacodynamic, pharmacokinetic and toxicological properties of telmisartan and amlodipine combination are well known. Since these two substances are a widely used, wellknown active substance, no further studies are provided. Therefore, overview based on literature review is appropriat ...
Revised: June 2016 AN: 00212/2016 SUMMARY OF PRODUCT
Revised: June 2016 AN: 00212/2016 SUMMARY OF PRODUCT

... difficulty in breathing are more serious symptoms and require urgent medical attention. 4.6 Adverse reactions (frequency and seriousness) Gastrointestinal signs may sometimes be observed (diarrhea). Penicillins may cause allergic reactions after the administration of the product. Allergic reactions ...
History of psychopharmacology
History of psychopharmacology

... 1950s, approximately 500,000 individuals resided within mental institutions in the United States of America. However, the development and utilisation of pharmacologic interventions saw this figure dramatically decrease to approximately 200,000 in-patients within 10 years (Sherr, 2000). The term psyc ...
8BD 039  2 '03  JAN 24  AtI  114
8BD 039 2 '03 JAN 24 AtI 114

... Next you will find examples of some single entity combination products, including PersistTM and Persist Plus TM,which are sold both as kit components and individually, and flush syringes. Attachment 3 shows the draft Persist site prep label, in actual size. We have not yet been able to finalize the ...
May  18,200O
May 18,200O

... the risk of heart attack even for patients who show no signs of heart disease. Statin products that have a long history of safe use and minimal side effects could be used safely and responsibly in an OTC setting. For people who continue to struggle with elevated cholesterol levels despite healthy di ...
NIHRRWDRickLonesFeb2012approved
NIHRRWDRickLonesFeb2012approved

... “RCTs, long regarded at the ‘gold standard' of evidence, have been put on an undeserved pedestal. Their appearance at the top of ‘hierarchies’ of evidence is inappropriate; and hierarchies, themselves, are illusory tools for assessing evidence. They should be replaced by a diversity of approaches th ...
Phenylpropanolamine and Hemorrhagic Stroke in the Hemorrhagic
Phenylpropanolamine and Hemorrhagic Stroke in the Hemorrhagic

Tek501/676-Z191 h XI1/676.3211 . Dockets Management
Tek501/676-Z191 h XI1/676.3211 . Dockets Management

... expertise; foreign counhy’s Post-market history for that drug use animal Safety, efficacy, etc. Some countries may not require registnition for non-food, minor species use based on their drug laws or policy. The basis for this policy cotild be evaluated by FDA to determine validity for minor yses. . ...
Omacor® capsules (post MI)
Omacor® capsules (post MI)

... beta-blockers) was much lower. The much lower use of these alternative secondary prevention measures is likely to have resulted in the trial overestimating the benefits of Omacor®. In addition the trial had very high dietary consumption of fish, fresh vegetables and olive oil, described by many as a ...
Ildong Pharmaceutical Receives a Marketing and
Ildong Pharmaceutical Receives a Marketing and

... Ph.D.; hereafter “Shionogi” or “the Company”) today announced that ILDONG PHARMACEUTICAL Co., Ltd. (Head Office: Seoul; Chairman & CEO: Jung-chi Lee; hereafter “ILDONG”) received a marketing and manufacturing approval for idiopathic pulmonary fibrosis (IPF) treatment of Pirespa® 200mg tablet (generi ...
PK - 11-19
PK - 11-19

Moberg Pharma launches innovative new Kerasal product in the U.S.
Moberg Pharma launches innovative new Kerasal product in the U.S.

Psychopharmacology:
Psychopharmacology:

... The receptor for a drug can be defined as the cellular component to which the drug binds and through which the drug initiates its pharmacodynamic effects on the body.  The drug can be an agonist(stimulant of the biological activity of the receptor) or an antagonist(inhibits the biological activity ...
Product Monograph
Product Monograph

... infection, see your healthcare provider to get treatment. Wait until the infection is gone before using Zestra® Additional information on use: ...
Slide set - Perelman School of Medicine at the University of
Slide set - Perelman School of Medicine at the University of

... prospect of direct benefit.” Prior to this amendment, only the safety of drugs was considered ...
Kishore Herbstman
Kishore Herbstman

... of statin should ultimately be left to individual nations. To ensure safety, we recommended that patients seek medical care in the first year of treatment to be monitored for liver-function impairment and evaluated for rhabdomyolysis—adverse effects that are consistent throughout populations. Curren ...
Chapter
Chapter

... give approval for marketing a new drug or approving a new use for an older drug. FDA approval involves a 4-step process ...
23900700150 - Madhya Pradesh Commercial Tax Appellate Board
23900700150 - Madhya Pradesh Commercial Tax Appellate Board

... proof of the fact that the preparation for which license has bee' issued is a drug within the meaning of the r 940 Act. Further reliance has been placed by the Revenue in the case of Balaii Agencies Gorakhpur v/s cST (1993) srl 532 (Alrah) wherein lt . was decided that every cosmetic usually has som ...
Federal Law - PassAssured Student login
Federal Law - PassAssured Student login

... approval was given by the FDA for marketing ...
AACC urges FDA to permit responsible laboratories continued
AACC urges FDA to permit responsible laboratories continued

Pharmacogenomics and Personalized Medicine
Pharmacogenomics and Personalized Medicine

...  ADRs are typically the 5th leading cause of death in the United States and are one of the leading, preventable public health issues today.  In terms of total health care dollars, ADRs cost the U.S. health care system between $1.5 and $5.4 billion per year. ...
< 1 ... 154 155 156 157 158 159 160 161 162 ... 193 >

Biosimilar

A biosimilar (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is a copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original ""innovator"" products, and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.Unlike the more common small-molecule drugs, biologics generally exhibit high molecular complexity, and may be quite sensitive to changes in manufacturing processes. Follow-on manufacturers do not have access to the originator's molecular clone and original cell bank, nor to the exact fermentation and purification process, nor to the active drug substance. They do have access to the commercialized innovator product.Drug related authorities such as European Medicines Agency (EMA), Food and Drug Administration (FDA), and Health Canada hold their own guidance on requirements for demonstration of the similar nature of two biological products in terms of safety and efficacy. According to them, analytical studies that demonstrate that the biological product is highly similar to the reference product notwithstanding minor differences in clinically inactive components; animal studies (including the assessment of toxicity); and a clinical study or studies (including the assessment of immunogenicity and pharmacokinetics or pharmacodynamics) that are sufficient to demonstrate safety, purity, and potency in one or more appropriate conditions of use for which the reference product is licensed and intended to be used and for which licensure is sought for the biological product.In case of a monoclonal antibody-containing medicinal product, such as Remsima, extensive physicochemical and biological characterization for it and its reference product Remicade was conducted in order to demonstrate their highly similar properties. Consequently, EMA have granted a marketing authorisation for only a few numbers of biosimilars since 2006 including a monoclonal antibody which is recently approved. Meanwhile, on March 6, 2015, the FDA approved the United States's first biosimilar product, the biosimilar filgrastim Zarxio.
  • studyres.com © 2025
  • DMCA
  • Privacy
  • Terms
  • Report